Issued on behalf of Aleen Inc.

VANCOUVER – USA News Group News Commentary – Healthcare organizations tripled their AI spending to $1.4 billion in 2025[1] as artificial intelligence platforms expand beyond isolated applications into comprehensive systems spanning prevention, diagnostics and drug discovery. Industry leaders are deploying AI infrastructure across the entire care continuum, with digital wellness platforms analyzing user health patterns, imaging systems validating clinical decisions in real time, and pharmaceutical companies building AI supercomputers to accelerate molecule design[2]. This convergence reflects a fundamental shift as healthcare and wellness providers, technology companies and pharmaceutical giants race to establish AI as core infrastructure rather than experimental add-ons. Among the companies capturing this momentum are Aleen Inc. (CSE: ALEN-U), GE HealthCare (NASDAQ: GEHC), RadNet, Inc. (NASDAQ: RDNT), Eli Lilly and Company (NYSE: LLY), and NVIDIA (NASDAQ: NVDA).

Market analysts project the global AI healthcare sector will reach $701.79 billion by 2034, expanding from $37.09 billion in 2025 at a 38.6% compound annual growth rate[3]. The accelerated adoption comes as healthcare systems face mounting pressure from aging populations, chronic disease burdens and workforce shortages, creating urgent demand for platforms that can automate administrative tasks, enhance diagnostic accuracy and enable proactive intervention before conditions escalate into costly treatments[4].

Aleen Inc. (CSE: ALEN-U), a Canadian technology company operating in the digital wellness space, has completed its initial concept testing for the upcoming Smart Analytics feature. The research highlighted three recurring user expectations: clear visualization of personal wellness patterns, strong privacy safeguards and control over any information they choose to share , and simple, non-medical interpretation of structured inputs. These findings confirm Aleen Inc.’s focus on balance between clarity, autonomy, and usability as the company continues developing responsible, insight-based technologies that help users stay informed about their well-being without replacing professional consultation.

The company previously announced it was beginning early concept testing for smart wellness analytics, building on its initiative to enhance personalized interpretation of wellness information. “Our current focus is on understanding how an analytical tool can responsibly support everyday well-being — while staying entirely outside the realm of diagnostic or medical functions,” said Anastasiia Kalashnik, PR Specialist of Aleen Inc. “We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions.”

Based in Ontario, Aleen Inc. went public on the Canadian Securities Exchange in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The testing phase focused on assessing real user needs and expectations, exploring potential analytical approaches that could simplify recognition of trends over time, and conducting scenario-based evaluations to understand how structured insights might enhance personal well-being awareness.

Aleen Inc. operates in a rapidly expanding market. The global digital wellness sector is currently valued at approximately $12.87 billion in 2025 and is projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen Inc. is positioned to capture a portion of this expanding demand.

The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen Inc.’s technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access.

Looking ahead to 2026, Aleen Inc. plans to launch personal user accounts that will allow individuals to securely store and organize their wellness information in one place, alongside introducing the smart analytics features currently in testing. To fund these initiatives, Aleen Inc. is currently seeking between $20 million and $30 million in strategic investment. The company plans to allocate 35% of these funds toward technology development, 30% toward sales and marketing efforts, and 20% for product expansion including mobile apps and specialized modules for corporate wellness programs.

With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman. The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals. Aleen Inc. does not provide medical diagnoses and is not regulated as a medical device by the FDA or other health authorities.

CONTINUED… Read this and more news for Aleen Inc. at:

AI Engine Replaces The Waiting Room: Powering The $660B Health Revolution

GE HealthCare (NASDAQ: GEHC) expanded its AI-driven imaging footprint through a new letter of intent with RadNet’s DeepHealth division. The deal focuses on accelerating adoption of DeepHealth’s Thyroid Suite, breast-imaging AI and TechLive remote-scanning tools across GE HealthCare’s ultrasound portfolio.

“Our relationship with DeepHealth is a powerful example of how we are advancing our precision care through intelligent technology and a collaborative platform strategy,” said Karley Yoder, CEO of Comprehensive Care Ultrasound, Advanced Visualization Solutions at GE HealthCare. “We look forward to incorporating DeepHealth Thyroid Suite and TechLive into our ultrasound portfolio, and enhancing the capabilities of clinicians to make faster, more confident decisions while helping ensure patients benefit from the best our technology can offer.”

RadNet, Inc. (NASDAQ: RDNT) is seeing strong validation for its AI platform, with Thyroid Suite reducing exam time by up to 30% and radiologists accepting AI-generated reports without modification in over 94% of reviewed nodules. These results highlight DeepHealth’s potential to materially improve throughput, accuracy and diagnosis consistency across RadNet’s national imaging network.

“Together with GE HealthCare, we are advancing a new standard of AI-powered care for better outcomes, improved patient experience and more efficient workflows,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health Division, DeepHealth. “By uniting imaging, informatics and AI, we aim to detect disease earlier and more accurately, enable greater operational efficiency and increase patient access to high-quality care.”

Eli Lilly and Company (NYSE: LLY) has partnered with NVIDIA (NASDAQ: NVDA) to develop a next-generation AI supercomputer using over 1,000 B300 GPUs to drive model training, molecule design and digital manufacturing. The effort positions Lilly as one of the first pharmaceutical companies operating a pharma-scale “AI factory” for end-to-end drug discovery.

“Lilly’s mission is to make life better for people around the world, and today that requires excellence not just in science but also in technology,” said Diogo Rau, executive vice president and chief information and digital officer at Eli Lilly and Company. “I don’t believe any other company in our industry is doing what we do at this scale. As a 150-year-old medicine company, one of our most powerful assets is decades of data. With purpose-built AI models and AI, we can set a new scientific standard that accelerates innovation to deliver medicines to more patients, faster.”

NVIDIA’s healthcare stack will power new AI agents, multi-modal models, imaging pipelines and TuneLab workflows for Lilly’s scientists and external partners. This collaboration positions both companies at the center of the industry’s shift toward AI-native R&D, enabling faster cycle times, higher predictive accuracy and more scalable digital infrastructure in drug development.

“The AI industrial revolution will have its most profound impact on medicine, transforming how we understand biology,” said Kimberly Powell, vice president of health care at NVIDIA. “Modern AI factories are becoming the new instrument of science — enabling the shift from trial-and-error discovery to a more intentional design of medicines. With its deep scientific heritage and commitment to innovation, Lilly stands as a global leader at the forefront of this new era of medical discovery.”

Article Sources: https://usanewsgroup.com/2025/10/25/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/

CONTACT:

USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen’s solutions operate within the wellness domain and are not subject to FDA or Health Canada approval.

—

SOURCES:
1. https://menlovc.com/perspective/2025-the-state-of-ai-in-healthcare/
2. https://www.biospace.com/press-releases/ai-in-healthcare-market-to-hit-usd-701-79-billion-by-2034
3. https://www.biospace.com/press-releases/ai-in-healthcare-market-to-hit-usd-701-79-billion-by-2034
4. https://hitconsultant.net/2025/11/13/digital-health-meets-life-insurance-how-technology-is-redefining-financial-protection-and-preventive-care/